392 related articles for article (PubMed ID: 11710724)
1. A double-blind trial of colchicine in Behçet's syndrome.
Yurdakul S; Mat C; Tüzün Y; Ozyazgan Y; Hamuryudan V; Uysal O; Senocak M; Yazici H
Arthritis Rheum; 2001 Nov; 44(11):2686-92. PubMed ID: 11710724
[TBL] [Abstract][Full Text] [Related]
2. Pharmacotherapy for Behcet's syndrome.
Saenz A; Ausejo M; Shea B; Wells G; Welch V; Tugwell P
Cochrane Database Syst Rev; 2000; 1998(2):CD001084. PubMed ID: 10796413
[TBL] [Abstract][Full Text] [Related]
3. A double-blind trial of depot corticosteroids in Behçet's syndrome.
Mat C; Yurdakul S; Uysal S; Gogus F; Ozyazgan Y; Uysal O; Fresko I; Yazici H
Rheumatology (Oxford); 2006 Mar; 45(3):348-52. PubMed ID: 16263779
[TBL] [Abstract][Full Text] [Related]
4. Colchicine versus placebo in Behçet's disease: randomized, double-blind, controlled crossover trial.
Davatchi F; Sadeghi Abdollahi B; Tehrani Banihashemi A; Shahram F; Nadji A; Shams H; Chams-Davatchi C
Mod Rheumatol; 2009; 19(5):542-9. PubMed ID: 19597921
[TBL] [Abstract][Full Text] [Related]
5. Effect of prophylactic benzathine penicillin on mucocutaneous symptoms of Behçet's disease.
Calgüneri M; Ertenli I; Kiraz S; Erman M; Celik I
Dermatology; 1996; 192(2):125-8. PubMed ID: 8829493
[TBL] [Abstract][Full Text] [Related]
6. Colchicine in the treatment of the cutaneous manifestations of Behçet's disease.
Miyachi Y; Taniguchi S; Ozaki M; Horio T
Br J Dermatol; 1981 Jan; 104(1):67-9. PubMed ID: 7459271
[TBL] [Abstract][Full Text] [Related]
7. Trial of Apremilast for Oral Ulcers in Behçet's Syndrome.
Hatemi G; Mahr A; Ishigatsubo Y; Song YW; Takeno M; Kim D; Melikoğlu M; Cheng S; McCue S; Paris M; Chen M; Yazici Y
N Engl J Med; 2019 Nov; 381(20):1918-1928. PubMed ID: 31722152
[TBL] [Abstract][Full Text] [Related]
8. Behçet's syndrome: facts and controversies.
Mat C; Yurdakul S; Sevim A; Özyazgan Y; Tüzün Y
Clin Dermatol; 2013; 31(4):352-361. PubMed ID: 23806152
[TBL] [Abstract][Full Text] [Related]
9. Thalidomide in the treatment of the mucocutaneous lesions of the Behçet syndrome. A randomized, double-blind, placebo-controlled trial.
Hamuryudan V; Mat C; Saip S; Ozyazgan Y; Siva A; Yurdakul S; Zwingenberger K; Yazici H
Ann Intern Med; 1998 Mar; 128(6):443-50. PubMed ID: 9499327
[TBL] [Abstract][Full Text] [Related]
10. Erythema nodosum-like lesions in Behçet's disease: a clinicopathological study of 26 cases.
Misago N; Tada Y; Koarada S; Narisawa Y
Acta Derm Venereol; 2012 Nov; 92(6):681-6. PubMed ID: 22504656
[TBL] [Abstract][Full Text] [Related]
11. Apremilast for Behçet's syndrome--a phase 2, placebo-controlled study.
Hatemi G; Melikoglu M; Tunc R; Korkmaz C; Turgut Ozturk B; Mat C; Merkel PA; Calamia KT; Liu Z; Pineda L; Stevens RM; Yazici H; Yazici Y
N Engl J Med; 2015 Apr; 372(16):1510-8. PubMed ID: 25875256
[TBL] [Abstract][Full Text] [Related]
12. Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behçet's disease.
Masuda K; Nakajima A; Urayama A; Nakae K; Kogure M; Inaba G
Lancet; 1989 May; 1(8647):1093-6. PubMed ID: 2566048
[TBL] [Abstract][Full Text] [Related]
13. Recurrent epididymo-orchitis in patients with Behçet's disease.
Kaklamani VG; Vaiopoulos G; Markomichelakis N; Kaklamanis P
J Urol; 2000 Feb; 163(2):487-9. PubMed ID: 10647662
[TBL] [Abstract][Full Text] [Related]
14. The Effect of Colchicine on Mean Platelet Volume in Behcet's Disease.
Ataş H; Cemil BC; Canpolat F; Gönül M
Ann Clin Lab Sci; 2015; 45(5):545-9. PubMed ID: 26586706
[TBL] [Abstract][Full Text] [Related]
15. Prognosis of Behcet's syndrome among men with mucocutaneous involvement at disease onset: long-term outcome of patients enrolled in a controlled trial.
Hamuryudan V; Hatemi G; Tascilar K; Sut N; Ozyazgan Y; Seyahi E; Mat C; Yurdakul S; Yazici H
Rheumatology (Oxford); 2010 Jan; 49(1):173-7. PubMed ID: 19995858
[TBL] [Abstract][Full Text] [Related]
16. Interferon alfa-2b, colchicine, and benzathine penicillin versus colchicine and benzathine penicillin in Behçet's disease: a randomised trial.
Demiroglu H; Ozcebe OI; Barista I; Dündar S; Eldem B
Lancet; 2000 Feb; 355(9204):605-9. PubMed ID: 10696980
[TBL] [Abstract][Full Text] [Related]
17. Guidelines for the treatment of skin and mucosal lesions in Behçet's disease: A secondary publication.
Nakamura K; Iwata Y; Asai J; Kawakami T; Tsunemi Y; Takeuchi M; Mizuki N; Kaneko F;
J Dermatol; 2020 Mar; 47(3):223-235. PubMed ID: 31907947
[TBL] [Abstract][Full Text] [Related]
18. Frequent oral ulceration during early disease may predict a severe disease course in males with Behçet's syndrome.
Hamuryudan V; Hatemi G; Sut N; Ugurlu S; Yurdakul S; Yazici H
Clin Exp Rheumatol; 2012; 30(3 Suppl 72):S32-4. PubMed ID: 22935508
[TBL] [Abstract][Full Text] [Related]
19. Treatment of mucocutaneous manifestations in Behçet's disease with anakinra: a pilot open-label study.
Grayson PC; Yazici Y; Merideth M; Sen HN; Davis M; Novakovich E; Joyal E; Goldbach-Mansky R; Sibley CH
Arthritis Res Ther; 2017 Mar; 19(1):69. PubMed ID: 28335798
[TBL] [Abstract][Full Text] [Related]
20. Short-term trial of etanercept in Behçet's disease: a double blind, placebo controlled study.
Melikoglu M; Fresko I; Mat C; Ozyazgan Y; Gogus F; Yurdakul S; Hamuryudan V; Yazici H
J Rheumatol; 2005 Jan; 32(1):98-105. PubMed ID: 15630733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
